- Home
- CRBP vs GDO Comparison
CRBP vs GDO Comparison
Compare CRBP & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- GDO
- Stock Information
- Founded
- CRBP 2009
- GDO 2009
- Country
- CRBP United States
- GDO United States
- Employees
- CRBP N/A
- GDO N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- GDO Finance Companies
- Sector
- CRBP Health Care
- GDO Finance
- Exchange
- CRBP Nasdaq
- GDO Nasdaq
- Market Cap
- CRBP 73.4M
- GDO 82.4M
- IPO Year
- CRBP N/A
- GDO N/A
- Fundamental
- Price
- CRBP $6.65
- GDO $11.41
- Analyst Decision
- CRBP Strong Buy
- GDO
- Analyst Count
- CRBP 10
- GDO 0
- Target Price
- CRBP $53.56
- GDO N/A
- AVG Volume (30 Days)
- CRBP 148.0K
- GDO 39.4K
- Earning Date
- CRBP 05-06-2025
- GDO 01-01-0001
- Dividend Yield
- CRBP N/A
- GDO 9.81%
- EPS Growth
- CRBP N/A
- GDO N/A
- EPS
- CRBP N/A
- GDO N/A
- Revenue
- CRBP N/A
- GDO N/A
- Revenue This Year
- CRBP N/A
- GDO N/A
- Revenue Next Year
- CRBP $150.00
- GDO N/A
- P/E Ratio
- CRBP N/A
- GDO N/A
- Revenue Growth
- CRBP N/A
- GDO N/A
- 52 Week Low
- CRBP $4.64
- GDO $11.21
- 52 Week High
- CRBP $61.90
- GDO $13.04
- Technical
- Relative Strength Index (RSI)
- CRBP 48.86
- GDO 55.24
- Support Level
- CRBP $6.10
- GDO $11.35
- Resistance Level
- CRBP $8.07
- GDO $11.50
- Average True Range (ATR)
- CRBP 0.70
- GDO 0.13
- MACD
- CRBP -0.07
- GDO 0.04
- Stochastic Oscillator
- CRBP 26.50
- GDO 76.85
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.